[8-K] NEKTAR THERAPEUTICS Reports Material Event

Rhea-AI Filing Summary

Nektar Therapeutics announced that Mark A. Wilson will step down as Chief Legal Officer, effective December 31, 2025. The company states that his departure is not due to any disagreement regarding Nektar’s operations, policies, or practices, which indicates this is presented as an orderly transition rather than a dispute-driven change.

Elizabeth Zhang, currently Vice President, Legal and Corporate Counsel, will assume Mr. Wilson’s responsibilities. She joined Nektar in 2021 and previously worked at major law firms Cravath, Swaine & Moore LLP and Gibson, Dunn & Crutcher LLP. Ms. Zhang holds degrees from Harvard College, the University of Oxford, and Harvard Law School, suggesting continuity in legal leadership with a strong academic and professional background.

false 0000906709 0000906709 2025-11-21 2025-11-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 21, 2025

NEKTAR THERAPEUTICS

(Exact Name of Registrant as Specified in Charter)

Delaware		0-24006		94-3134940
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

455 Mission Bay Boulevard South

San Francisco, California 94158

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: (415) 482-5300

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value		NKTR		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On November 21, 2025, Nektar Therapeutics (“Nektar”) announced that Mark A. Wilson will step down as Chief Legal Officer of Nektar, effective as of December 31, 2025. Mr. Wilson’s departure is not the result of any disagreement with Nektar on any matter relating to its operations, policies or practices.

Elizabeth Zhang, Nektar's Vice President, Legal and Corporate Counsel, will be taking over Mr. Wilson's responsibilities. Ms. Zhang has been with Nektar since 2021 after prior positions at Cravath, Swaine & Moore LLP in New York City and Gibson, Dunn & Crutcher LLP in San Francisco. 

Ms. Zhang holds a Bachelor of Arts in Neurobiology from Harvard College, a Master of Science in Neuroscience from the University of Oxford, and a Juris Doctor from Harvard Law School.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NEKTAR THERAPEUTICS
Date: November 21, 2025	By:	/s/ Mark A. Wilson
		Mark A. Wilson
		Chief Legal Officer and Secretary

2

FAQ

What did Nektar Therapeutics (NKTR) announce in this Form 8-K?

Nektar Therapeutics announced that Chief Legal Officer Mark A. Wilson will step down effective December 31, 2025, and that Elizabeth Zhang will take over his responsibilities.

Why is Nektar Therapeutics’ Chief Legal Officer leaving?

Nektar states that Mr. Wilson’s departure is not the result of any disagreement with the company on matters related to its operations, policies, or practices.

Who will replace the Chief Legal Officer at Nektar Therapeutics (NKTR)?

Elizabeth Zhang, currently Vice President, Legal and Corporate Counsel at Nektar, will assume Mr. Wilson’s responsibilities after he steps down.

What is Elizabeth Zhang’s background at Nektar Therapeutics?

Elizabeth Zhang has been with Nektar since 2021 and serves as Vice President, Legal and Corporate Counsel, taking over the responsibilities of the Chief Legal Officer.

What are Elizabeth Zhang’s educational qualifications?

Ms. Zhang holds a B.A. in Neurobiology from Harvard College, an M.S. in Neuroscience from the University of Oxford, and a J.D. from Harvard Law School.

Does Nektar mention any disagreement related to this executive change?

Nektar explicitly states that Mr. Wilson’s departure is not due to any disagreement with the company about its operations, policies, or practices.